Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in pediatric episodic migraine
NCT03432286Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of galcanezumab in episodic migraine, sponsored by Eli Lilly and Company. Started Mar 2018; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03432286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432286.